CN105456620A - 一种用于治疗多囊卵巢综合征合并乳腺增生的药物组合物 - Google Patents
一种用于治疗多囊卵巢综合征合并乳腺增生的药物组合物 Download PDFInfo
- Publication number
- CN105456620A CN105456620A CN201610094506.2A CN201610094506A CN105456620A CN 105456620 A CN105456620 A CN 105456620A CN 201610094506 A CN201610094506 A CN 201610094506A CN 105456620 A CN105456620 A CN 105456620A
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- pharmaceutical composition
- polycystic ovarian
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 32
- 201000010065 polycystic ovary syndrome Diseases 0.000 title claims abstract description 31
- 206010036049 Polycystic ovaries Diseases 0.000 title claims abstract description 25
- 206010006256 Breast hyperplasia Diseases 0.000 title abstract 4
- 239000003814 drug Substances 0.000 claims abstract description 46
- 238000002360 preparation method Methods 0.000 claims abstract description 22
- 238000011282 treatment Methods 0.000 claims description 59
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 241000688694 Cheilanthes argentea Species 0.000 claims description 22
- 241000628997 Flos Species 0.000 claims description 22
- 239000002775 capsule Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 7
- 239000012567 medical material Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 238000003809 water extraction Methods 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 3
- 239000007901 soft capsule Substances 0.000 claims description 3
- -1 sublimed preparation Substances 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 abstract description 24
- 210000003734 kidney Anatomy 0.000 abstract description 22
- 210000004369 blood Anatomy 0.000 abstract description 21
- 239000008280 blood Substances 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 17
- 229940079593 drug Drugs 0.000 abstract description 15
- 230000008961 swelling Effects 0.000 abstract description 10
- 230000007812 deficiency Effects 0.000 abstract description 8
- 230000005906 menstruation Effects 0.000 abstract description 8
- 230000001105 regulatory effect Effects 0.000 abstract description 8
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 206010067484 Adverse reaction Diseases 0.000 abstract description 3
- 230000006838 adverse reaction Effects 0.000 abstract description 3
- 241000183291 Aleuritopteris Species 0.000 abstract 1
- 241001233914 Chelidonium majus Species 0.000 abstract 1
- 244000150195 Cyperus longus Species 0.000 abstract 1
- 241000893536 Epimedium Species 0.000 abstract 1
- 235000004789 Rosa xanthina Nutrition 0.000 abstract 1
- 241000109329 Rosa xanthina Species 0.000 abstract 1
- 240000003705 Senecio vulgaris Species 0.000 abstract 1
- 241001302210 Sida <water flea> Species 0.000 abstract 1
- 241001300193 Speranskia Species 0.000 abstract 1
- 240000006694 Stellaria media Species 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 235000018905 epimedium Nutrition 0.000 abstract 1
- 235000008216 herbs Nutrition 0.000 abstract 1
- 230000007721 medicinal effect Effects 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 25
- 230000036407 pain Effects 0.000 description 25
- 210000000481 breast Anatomy 0.000 description 20
- 210000001672 ovary Anatomy 0.000 description 14
- 239000000796 flavoring agent Substances 0.000 description 13
- 230000001737 promoting effect Effects 0.000 description 13
- 230000006870 function Effects 0.000 description 12
- 235000019634 flavors Nutrition 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 8
- 208000019255 Menstrual disease Diseases 0.000 description 7
- 230000002146 bilateral effect Effects 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 7
- 230000027758 ovulation cycle Effects 0.000 description 7
- 231100000614 poison Toxicity 0.000 description 7
- 238000005728 strengthening Methods 0.000 description 7
- 239000003440 toxic substance Substances 0.000 description 7
- 201000000736 Amenorrhea Diseases 0.000 description 6
- 206010001928 Amenorrhoea Diseases 0.000 description 6
- 231100000540 amenorrhea Toxicity 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 210000005075 mammary gland Anatomy 0.000 description 6
- 208000004396 mastitis Diseases 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 235000014347 soups Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 230000004087 circulation Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 208000021267 infertility disease Diseases 0.000 description 4
- 230000002611 ovarian Effects 0.000 description 4
- 208000037920 primary disease Diseases 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 206010006298 Breast pain Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 208000006662 Mastodynia Diseases 0.000 description 3
- 208000009205 Tinnitus Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000002175 menstrual effect Effects 0.000 description 3
- 238000004080 punching Methods 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 231100000886 tinnitus Toxicity 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 201000005670 Anovulation Diseases 0.000 description 2
- 206010002659 Anovulatory cycle Diseases 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 206010020112 Hirsutism Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 231100000552 anovulation Toxicity 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 2
- 229960003608 clomifene Drugs 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 201000010066 hyperandrogenism Diseases 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003821 menstrual periods Effects 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 210000004994 reproductive system Anatomy 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 208000034579 Acute haemorrhagic conjunctivitis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 240000004859 Gamochaeta purpurea Species 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021033 Hypomenorrhoea Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010049949 Intercostal neuralgia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024419 Libido decreased Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 208000030270 breast disease Diseases 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- RWYFURDDADFSHT-RBBHPAOJSA-N diane Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1=C(Cl)C2=CC(=O)[C@@H]3CC3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RWYFURDDADFSHT-RBBHPAOJSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000028659 discharge Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000003958 fumigation Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 208000001581 lymphogranuloma venereum Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000009607 mammography Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000001931 thermography Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于医药技术领域,涉及一种用于治疗多囊卵巢综合征合并乳腺增生的药物组合物及其制备方法。该药物组合物由熟地黄、隔山消、千针万线草、玫瑰花、老鸦花藤、淫羊藿、蛋不老、通经草、香附、黄花稔、天葵草为药用原料精心制成。全方合伍具有补肾疏肝,活血调经,养血益气,散结消肿之功效,本发明肝肾并补,阴阳同调,尤其针对肾虚肝郁型多囊卵巢综合征合并乳腺增生的患者而研制。本发明组方精简,配伍合理,成本低廉,经临床应用验证,其疗效确切,药性平和,未出现毒副作用及明显不良反应,安全系数高。
Description
技术领域
本发明属于医药技术领域,涉及一种用于治疗多囊卵巢综合征合并乳腺增生的药物组合物及其制备方法。
背景技术
多囊卵巢综合征(polycysticovarysyndrome,PCOS)是一种与糖代谢异常和生殖功能障碍高度相关的疾病,多发于青春期少女和育龄期妇女,其临床表现具有多样性和异质性,主要表现为持续无排卵、闭经或月经稀发、多毛和肥胖及不孕等。据其临床表现当属“月经后期”、“闭经”、“不孕”等范畴。多囊卵巢综合征严重影响妇女的生命质量,除月经失调、不孕等近期并发症外还带来心血管疾患、子宫内膜癌等远期并发症。据报道正常卵巢者乳腺增生发生率仅为6.5%,而PCOS患者中乳腺增生的发生率高达60%以上。
乳腺增生是一种与内分泌功能紊乱有关的疾病,属中医“乳癖”范畴。现代医学认为本病与卵巢的内分泌状态密切相关。乳腺为性激素作用的靶器官,不仅是女性最显著的第二性征,也是广义生殖系统中的一个组成部分。乳腺的生理变化与月经周期变化是一致的。乳腺增生症的发病主要是内分泌激素失调的观点己被大多数学者公认。乳腺与卵巢、子宫具有相同的靶细胞,当各种原因导致内分泌失调,雌激素分泌紊乱时,会同时影响乳腺及生殖系统而引起妇科病及乳腺增生症。
对于PCOS常用的治疗方法有西医疗法、中医疗法及中西医结合疗法。西医疗法有药物治疗和手术治疗两种,药物治疗仅限于对症治疗,如克罗米芬促排卵治疗、雌-孕激素替代疗法、达英35治疗高雄激素血症、口服二甲双肌以改善胰岛素抵抗状态等。而克罗米芬促排治疗患者中乳腺增生症的患病率更高,患者月经失调及使用类雌激素药物情况与乳腺增生症呈正相关,因此对于多囊卵巢综合征合并乳腺增生的患者,中医治疗为首选,而目前尚未有针对多囊卵巢综合征合并乳腺增生的药物面世。中医治疗本病症有多系统调理的优势。因此,需要提出一种具有更好疗效的治疗女性多囊卵巢综合症合并乳腺增生的中药复合物。
发明内容
发明人以中医理论为基础,结合多囊卵巢综合征合并乳腺增生的病因病机,基于多年临床治疗经验,博采众长,苦心研究,为了克服现有技术的不足,本发明提供一种能够有效治疗多囊卵巢综合征合并乳腺增生而且见效快、疗程短、治愈率高的药物组合物。
为实现本发明的目的,现依据如下的技术方案:
一种用于治疗多囊卵巢综合征合并乳腺增生的药物组合物,其由熟地黄、隔山消、千针万线草、玫瑰花、老鸦花藤、淫羊藿、蛋不老、通经草、香附、黄花稔、天葵草为药用原料精心制成。
进一步优选地,一种治疗多囊卵巢综合征乳腺增生的药物组合物,其特征在于由以下重量份配比的药用原料精心制成:熟地黄10-15份、隔山消13-18份、千针万线草20-30份、玫瑰花8-12份、老鸦花藤15-20份、淫羊藿6-11份、蛋不老10-15份、通经草15-20份、香附6-9份、黄花稔8-12份、天葵草13-18份。
进一步优选地,一种治疗多囊卵巢综合征乳腺增生的药物组合物,其特征在于由以下重量份配比的药用原料精心制成:熟地黄12份、隔山消15份、千针万线草24份、玫瑰花10份、老鸦花藤15份、淫羊藿8份、蛋不老12份、通经草18份、香附8份、黄花稔11份、天葵草16份。
《外科医案汇编》:“乳中结核,虽云肝病,其病在肾”。肾主生殖,若肾精不足,冲任气血乏源,无以下注胞宫,则表现为经水后期或闭经;因肝气郁结,失于疏泄,影响冲任的通盛,同时气郁化火,灼伤肾阴,使肾中阴阳失衡,致使难以受孕,冲任经气不通,而发为乳房疼痛,肾阳不足,温煦无力,水湿内停,结于乳络而见乳房疼痛,肾虚肝郁为本病的基本病机。方中:熟地黄滋阴补血,益精填髓;隔山消滋阴养血,健脾理气,镇静止痛,二药伍用滋阴补血力强为君药。千针万线草健脾养血,补肝益肾,消肿;玫瑰花行气解郁,健脾降火,和血止痛;老鸦花藤强筋壮骨,补血调经,三药伍用活血行气,补血疏肝,为臣药。淫羊藿性温不寒,辛能散结,甘能缓中,温能通气行血,能益精气,补真阳不足,阳中育阴助君药以调理阴阳平衡;蛋不老祛风湿,通经络,破瘀止痛;通经草祛痰止咳,活血通经,解毒消肿;香附行气解郁,调经止痛;黄花稔解毒消肿,活血止痛;天葵草清热解毒,消肿散结,具为佐使药。全方合伍具有补肾疏肝,活血调经,养血益气,散结消肿之功效,本发明肝肾并补,阴阳同调,尤其针对肾虚肝郁型多囊卵巢综合征合并乳腺增生的患者而研制。
本发明中药所涉及药材的研究现状如下:
熟地黄:【性味】甘,微温。【归经】归肝、肾经。【功能主治】滋阴补血,益精填髓。用于肝肾阴虚,腰膝酸软,骨蒸潮热,盗汗遗精,内热消渴,血虚萎黄,心悸怔忡,月经不调,崩漏下血,眩晕,耳鸣,须发早白。【用法用量】9~15g。
隔山消:【性味】味甘;微苦;性微温;【归经】脾;胃;肾经。【功能主治】补肝肾;强筋骨;健脾胃;解毒。主肝肾两虚;头昏眼花;失眠健忘;须发早白;阳痿;遗精;腰膝酸攀登;脾虚不运;脘腹胀满;仞欲不振;泄泻;产后乳少;鱼口疮毒。【用法用量】内服:煎汤,9-15g外用:鲜品适量,捣敷。
淫羊藿:【性味】辛、甘,温。【归经】归肝、肾经。【功能主治】补肾阳,强筋骨,祛风湿。用于阳痿遗精,筋骨痿软,风湿痹痛,麻木拘挛;更年期高血压。【用法用量】3~9g。
老鸦花藤:【性味】苦,温。【功能主治】强筋壮骨,调经补血。主治小儿麻痹后遗症,贫血,月经不调,风湿筋骨痛。
蛋不老:【性味】苦;平。【归经】肺;肝;大肠经。【功能主治】祛风湿;通经络;破瘀止痛。主风湿痹痛;症瘕积聚;瘰疬;疔疮肿毒;跌打损伤。【用法用量】内服:煎汤,15-30g。外用:适量,捣敷;或煎水洗。
千针万线草:【性味】甘;性平。【归经】肝;脾;肾经。【功能主治】健脾养血;补肝益肾;消肿。主贫血;精神短少;头晕心慌;耳鸣眼花;潮热;遗精;月经不调;带下;骨折;乳腺炎。【用法用量】内服:煎汤,15-30g;或炖肉服。外用:适量,鲜品捣敷。
通经草:【性味】辛;甘;平。【归经】肺;肝经。【功能主治】祛痰止咳;活血通经;利湿;解毒消肿。主咳嗽;月经不调;经闭腹痛;赤白带下;肺痨咳血;大便泄泻;小便涩痛;肺痈;乳痈;风湿关节痛;跌打损伤;肋间神经痛;暴发火眼;疮肿。【用法用量】内服:煎汤,9-15g。外用:适量,水煎熏洗;或捣敷。
香附:【性味】辛、微苦、微甘,平。【归经】归肝、脾、三焦经。【功能主治】行气解郁,调经止痛。用于肝郁气滞,胸、胁、脘腹胀痛,消化不良,胸脘痞闷,寒疝腹痛,乳房胀痛,月经不调,经闭痛经。【用法用量】6~9g。
玫瑰花:【性味】甘、微苦,温。【归经】归肝、脾经。【功能主治】理气解郁,和血散瘀。治肝胃气痛,新久风痹,吐血咯血,月经不调,赤白带下,痢疾,乳痈,肿毒。
黄花稔:【性味】味辛;性凉。【归经】肺;肝;大肠经。【功能主治】清湿热;解毒消肿;活血止痛。主湿热泻痢;乳痈;痔疮;疮疡肿毒;跌打损伤;骨折;外伤出血。【用法用量】内服:煎汤,15-30g。外用:适量,捣敷或研粉撒敷。
天葵草:【性味】甘、苦,寒。【归经】归肝、胃经。【功能主治】:清热解毒,消肿散结。用于痈肿疔疮,乳痈,瘰疠,毒蛇咬伤。
为了更好地表达本发明的药物组合物,本发明药物组合物是由熟地黄、隔山消、千针万线草、玫瑰花、老鸦花藤、淫羊藿、蛋不老、通经草、香附、黄花稔、天葵草或其水或其有机溶剂提取物为活性成分,可加入药物可接受的载体,依照制剂学常规技术制成。
本发明的药物组合物可以是任何可药用的剂型,这些剂型包括:片剂、糖衣片剂、薄膜衣片剂、肠溶衣片剂、胶囊剂、硬胶囊剂、软胶囊剂、口服液、口含剂、颗粒剂、冲剂、丸剂、散剂、膏剂、丹剂、混悬剂、粉剂、溶液剂、注射剂、栓剂、软膏剂、硬膏剂、霜剂、喷雾剂、滴剂、贴剂。
上述所述的药物组合物优选的是口服剂型,如:软胶囊剂、胶囊剂、片剂、口服液、颗粒剂、丸剂、散剂、丹剂、膏剂;进一步优选为片剂、胶囊剂或颗粒剂;最优选为胶囊剂。
本发明的药物组合物,在制备成药剂时可选择性的加入适合的药物可接受的载体,所述药物可接受的载体选自可为填充剂、粘合剂、崩解剂、润滑剂、稀释剂、调味剂当中的一种或几种,如:填充剂、稀释剂可选淀粉、糖粉、糊精、微晶纤维素、乳糖、预胶化淀粉、甘露醇等;可选择的粘合剂有羧甲基纤维素钠、PVP-K30、羟丙基纤维素、淀粉浆、甲基纤维素、乙基纤维素、羟丙甲纤维素、胶化淀粉等;可选择的崩解剂有干淀粉、交联聚维酮、交联羧甲基纤维素钠、羧甲基淀粉钠,低取代羟丙基纤维素等;可选择的润滑剂有;硬脂酸镁、滑石粉、十二烷基硫酸钠、微粉硅胶等;调味剂如甜味素、阿斯巴甜等。
本发明还提供了一种上述所述药物组合物的制备方法。本发明的发明人在研究中发现,通过优化制备方法,能够在保持有效药物的情况下,去除杂质或无药效的部分,减少杂质对治疗效果的干扰,使得该中药制剂更加有效。
本发明提供的一种治疗多囊卵巢综合征乳腺增生的药物组合物的制备方法包括以下步骤:
按处方取熟地黄、隔山消、千针万线草、玫瑰花、老鸦花藤、淫羊藿、蛋不老、通经草、香附、黄花稔、天葵草,加4~7倍药材总重量的水提取2-3次,每次1~2小时,合并提取液,过滤,减压浓缩至相对密度为1.05-1.10(60℃测得),加乙醇使含醇量达45-50%(体积比),搅拌,静置过夜,过滤,滤液减压浓缩回收乙醇,浓缩成稠膏,该稠膏单独和/或与药物可接受的载体混合为活性成分,依照制剂学常规技术制成。
本发明是发明人经过反复研究,逐步改进,最后成功的一种疗效较好的治疗多囊卵巢综合征合并乳腺增生的药物,本发明对56例服用本发明药物的患者进行了临床观察,取得了较好的疗效,在56例患者中,总有效率为94.6%,与对照组总有效率比较,差异有统计学意义(P<0.05),经治疗后患者疼痛明显缓解,乳房肿块逐渐变软且逐渐变小,经检验治疗前后疼痛情况及肿块质地大小有显著性差异(P<0.05),有统计学意义;治疗组疼痛缓解情况及肿块大小变化情况优于对照组差异有统计学意义(P<0.05);治疗组治疗后双侧卵巢平均体积均有减小、卵泡总数目均有减少,且治疗前后差异均具有统计学意义(P<0.05)。对照组治疗前后差异无统计学意义(P>0.05)。可见本发明药物治疗多囊卵巢综合征合并乳腺增生优势明显,具有意料不到的技术效果,因此本发明还请求保护上述药物组合物在制备治疗多囊卵巢综合征合并乳腺增生尤其是肾虚肝郁型的药物中的用途以及上述药物组合物在制备治疗乳腺增生的药物中的用途。
本发明组方精简,配伍合理,成本低廉,经临床应用验证,其疗效确切,药性平和,未出现毒副作用及明显不良反应,安全系数高。
具体实施方式
以下通过具体实施例进一步描述本发明,本发明不仅仅限于以下实施例。在本发明的范围内或者在不脱离本发明的内容、精神和范围内,对本发明进行的变更、组合或替换,对于本领域的技术人员来说是显而易见的,且包含在本发明的范围之内。
实施例1胶囊剂
处方:熟地黄12份、隔山消15份、千针万线草24份、玫瑰花10份、老鸦花藤15份、淫羊藿8份、蛋不老12份、通经草18份、香附8份、黄花稔11份、天葵草16份。
制备方法:按处方取熟地黄、隔山消、千针万线草、玫瑰花、老鸦花藤、淫羊藿、蛋不老、通经草、香附、黄花稔、天葵草,加4~7倍药材总重量的水提取2-3次,每次1~2小时,合并提取液,过滤,减压浓缩至相对密度为1.05-1.10(60℃测得),加乙醇使含醇量达45-50%(体积比),搅拌,静置过夜,过滤,滤液减压浓缩回收乙醇,浓缩成稠膏,依照制剂学常规技术制成。
本实施例胶囊,每粒含有生药0.75g。
实施例2胶囊剂
处方:熟地黄10份、隔山消15份、千针万线草20份、玫瑰花8份、老鸦花藤15份、淫羊藿7份、蛋不老10份、通经草15份、香附7份、黄花稔10份、天葵草15份。
制备方法:参照实施例1进行。
实施例3胶囊剂
处方:熟地黄15份、隔山消18份、千针万线草30份、玫瑰花10份、老鸦花藤20份、淫羊藿10份、蛋不老15份、通经草15份、香附9份、黄花稔10份、天葵草13份。
制备方法:参照实施例1进行。
实施例4胶囊剂
处方:熟地黄15份、隔山消15份、千针万线草25份、玫瑰花8份、老鸦花藤20份、淫羊藿6份、蛋不老15份、通经草16份、香附9份、黄花稔12份、天葵草15份。
制备方法:参照实施例1进行。
实施例5胶囊剂
处方:熟地黄12份、隔山消15份、千针万线草25份、玫瑰花9份、老鸦花藤18份、淫羊藿9份、蛋不老10份、通经草15份、香附9份、黄花稔9份、天葵草18份。
制备方法:参照实施例1进行。
实施例6胶囊剂
处方:熟地黄12份、隔山消18份、千针万线草20份、玫瑰花12份、老鸦花藤18份、淫羊藿7份、蛋不老13份、通经草15份、香附8份、黄花稔8份、天葵草16份。
制备方法:参照实施例1进行。
实施例7片剂
处方:熟地黄12份、隔山消15份、千针万线草25份、玫瑰花10份、老鸦花藤17份、淫羊藿9份、蛋不老12份、通经草18份、香附8份、黄花稔11份、天葵草16份。
制备方法:按处方取熟地黄、隔山消、千针万线草、玫瑰花、老鸦花藤、淫羊藿、蛋不老、通经草、香附、黄花稔、天葵草,加4~7倍药材总重量的水提取2-3次,每次1~2小时,合并提取液,过滤,减压浓缩至相对密度为1.05-1.10(60℃测得),加乙醇使含醇量达45-50%(体积比),搅拌,静置过夜,过滤,滤液减压浓缩回收乙醇,浓缩成稠膏,依照制剂学常规技术制成。
本实施例制得的片剂,每片生药0.6g。
实施例8颗粒剂
处方:熟地黄15份、隔山消15份、千针万线草20份、玫瑰花12份、老鸦花藤15份、淫羊藿8份、蛋不老12份、通经草18份、香附6份、黄花稔10份、天葵草16份。
制备方法:按处方取熟地黄、隔山消、千针万线草、玫瑰花、老鸦花藤、淫羊藿、蛋不老、通经草、香附、黄花稔、天葵草,加4~7倍药材总重量的水提取2-3次,每次1~2小时,合并提取液,过滤,减压浓缩至相对密度为1.05-1.10(60℃测得),加乙醇使含醇量达45-50%(体积比),搅拌,静置过夜,过滤,滤液减压浓缩回收乙醇,浓缩成稠膏,依照制剂学常规技术制成。
实施例制得的颗粒剂,每袋含有生药3.0g。
实施例9临床观察试验
1资料与方法
1.1一般资料:观察2014年3月至2014年12月就诊于我院中医妇科门诊确诊为多囊卵巢综合征,同时患有乳腺增生症的患者112例,随机分为观察组与对照组进行观察,每组56例。观察组年龄25-36岁,平均年龄28.5±3.2岁,病程最长3.8年,最短6个月,平均1.75±0.83年。对照组年龄25-37岁,平均27.9±3.6岁;病程最长4.0年,最短7个月,平均1.86±0.71年。两组一般资料比较无统计学差异(P>0.05),具有可比性。
1.2诊断标准:
1.2.1PCOS的诊断标准:参照欧洲人类生殖协会(ESHRE)和美国生殖医学协会(ASRM)于2003年在鹿特丹研讨会制定的标准:符合以下3条中的任意2条:(l)长期无排卵;(2)雄激素水平升高的临床(如多毛、痤疮)和(或)生化依据;(3)卵巢增大,单侧卵巢体积>10ml或超声下至少有直径2~9mm的小卵泡>12个。除以上3条外,应排除其他疾病所致的雄激素增多症。
1.2.2乳腺增生症诊断标准:按国家中医药管理局1994年颁布的《中医病证诊断疗效标准》中“乳癖”的诊断依据:
(1)多数在乳房外上象限有一扁平肿块,扣之有豆粒大小韧硬结节,可有触痛。肿块边界欠清,与周围组织不粘连;
(2)乳房可有胀痛,每随喜怒而消长,常在月经前加重,月经后缓解;
(3)本病多见于20-40岁妇女;
(4)钼靶X线乳房摄片、冷光源强光照射、液晶热图像等检查有助诊断。必要时作组织病理学检查。
参照2002年中华中医外科学会乳腺病专业委员会第八次会议通过的有关乳癖的疗效评价参考标准,制定临床表现计分:
乳房疼痛:0级(6分)为无疼痛;1级(12分)为触压痛无自发痛;2级(18分)为自发痛呈阵发性;3级(24分)为自发痛呈持续性但不影响生活;4级(30分)为疼痛严重呈持续性且影响生活;
乳房肿块硬度:1级(3分)质软如正常腺体,2级(6分)质韧如鼻尖;3级(9分)质硬如额;
肿块范围:1级(3分)分布范围局限于1-2个乳房象限;2级(6分)分布范围达3-4个乳房象限;3级(9分)分布范围达5-6个乳房象限;4级(12分)分布范围达7-8个乳房象限;
乳房最大肿块直径:l级(3分)为2.0cm以下肿块;2级(6分)为2.1~5cm肿块;3级(9分)为5cm以上肿块.
1.2.3中医辨证分型标准:参照冷方南主编的《中医证候辨证规范》及李祥云主编的《实用妇科中西医诊断治疗学》中相关内容制定,采用临床病例的直接观察法,对不同类型的PCOS伴有乳腺增生症患者的中医证候进行分类,肾虚肝郁证型诊断标准进行辨证:
主症:①月经后期,量少,甚或闭经,或崩漏,不孕;②腰膝酸软,情志抑郁或心烦易怒;③乳房胀痛。次症:①头晕耳鸣,②性欲减退,③胸胁胀满,④口苦便秘,面色黯淡或痤疮;典型舌脉:舌质淡黯,有瘀点或瘀斑,脉沉弱或弦。
1.3入组及排除标准
1.3.1入组标准:符合上述多囊卵巢综合征和乳腺增生症的诊断标准;年龄在18-38岁之间女性;以乳腺症状为主,不并发全身严重症状,就诊前1个月未服用有关治疗乳腺增生的药物;知情同意并愿意配合治疗者。
1.3.2排除病例标准:妊娠、哺乳期或绝经期的妇女;合并有乳腺肿瘤、乳腺纤维瘤、乳腺炎等其他良性病变;有心血管、肝、肾和造血系统等严重原发性疾病;精神病患者;近3个月使用激素药物;过敏体质;符合纳入标准,未按规定用药;正在参加其他药物临床试验者;无法判断疗效或资料不全等影响疗效或安全性判断者。
1.4治疗方法:
治疗组:口服本发明实施例1制备的胶囊,每日2次,每次2-4粒,饭后半小时服用。一个月经周期为一疗程,逢经期减服或停服,共治疗3个疗程。
对照组:口服乳康舒胶囊,每日3次,每次3-4粒,一个月经周期为一疗程,逢经期减服或停服,共治疗3个疗程。
1.5观察指标:
1.5.1选择一最大的肿块作为靶肿块,观察治疗前、治疗3个周期后情况。
1.5.2观察治疗前、治疗3个周期后患者的月经改善情况,测定卵巢大小及多囊情况(卵巢体积=0.523*长径*前后径*横径,双侧卵巢平均体积=0.5*左右卵巢体积之和卵泡总数目取彩超下直径2-9mm的卵泡最多的双侧卵巢各一切面的卵泡数目之和)。
1.5.3观察治疗前、治疗3个周期后及停药后第3个周期患者的中医症状评分情况。
1.5.4检测肝功能水平,以观察两组的毒副反应情况。
1.6疗效评估标准:参照中华人民共和国卫生部《中药新药临床研究指导原则》及《中医病证诊断疗效标准》中的疗效标准进行判定:痊愈:月经恢复正常,临床症状明显减轻,B超提示卵巢恢复正常大小;n>90%;显效:月经接近正常周期,临床症状明显减轻,B超提示卵巢接近正常大小,90%>n≥66.67%;有效:治疗后月经周期不规则,临床症状有所减轻,B超提示卵巢较治疗前有所缩小,66.67%>n≥33.33%;无效:治疗后月经周期无改变,临床症状无明显改善,B超检查无明显改善,n<33.33%。总有效率=(痊愈+显效+有效)/总病例数X100%;疗效指数(n)=(疗前积分-疗后积分)/疗前积分X100%。
1.7统计学方法:采用SPSS15.0统计软件进行计算。各数值以表示,计量资料采用t检验,计数资料采用χ2检验,以P<0.05为差异有统计学意义。
2结果
2.1两组患者疗效比较:所有患者均完成临床试验,无脱落。治疗后治疗组痊愈18例,显效22例,有效13例,无效3例,总有效率94.6%;对照组痊愈7例,显效11例,有效20例,无效18例,总有效率67.9%,治疗组与对照组总有效率比较,差异有统计学意义(P<0.05),说明治疗组较对照组可以明显的提高多囊卵巢综合征合并乳腺增生患者的临床有效率。见表1。
表1两组患者疗效比较,例
注:与对照组比较,*P<0.05。
2.2两组治疗前后乳腺增生体征比较:治疗后两组疼痛明显缓解,乳房肿块逐渐变软且逐渐变小,经检验治疗前后疼痛情况及肿块质地大小有显著性差异(P<0.05),有统计学意义;治疗后两组间比较,治疗组疼痛缓解情况及肿块大小变化情况优于对照组差异有统计学意义(P<0.05),但肿块质地变化情况与对照组比较,差异无统计学意义(P>0.05)。见表2。
表2两组治疗前后乳腺增生体征比较
注:与治疗前比较,*P<0.05,与对照组同期比较,#P<0.05。
2.3两组治疗前后双侧卵巢体积及卵泡总数目比较:两组治疗前双侧卵巢的平均体积及卵泡总数目比较,差异不具有统计学意义(P>0.05),具有可比性;治疗组治疗后双侧卵巢平均体积均有减小、卵泡总数目均有减少,且治疗前后差异均具有统计学意义(P<0.05)。对照组治疗前后差异无统计学意义(P>0.05)。见表3。俥
表3两组治疗前后双侧卵巢体积及卵泡总数目比较
注:与治疗前比较,*P<0.05,与对照组同期比较,#P<0.05。
2.4两组副反应比较:两组均未诉不适,两组比较差异无统计学意义,两组均耐受良好。
总之:本发明组方精简,配伍合理,成本低廉,经临床应用验证,其疗效确切,药性平和,未出现毒副作用及明显不良反应,安全系数高。值得推广应用。
Claims (10)
1.一种用于治疗多囊卵巢综合征合并乳腺增生的药物组合物,其特征在于由熟地黄、隔山消、千针万线草、玫瑰花、老鸦花藤、淫羊藿、蛋不老、通经草、香附、黄花稔、天葵草为药用原料精心制成。
2.如权利要求1所述的药物组合物,其特征在于由以下重量份配比的药用原料制成:熟地黄10-15份、隔山消13-18份、千针万线草20-30份、玫瑰花8-12份、老鸦花藤15-20份、淫羊藿6-11份、蛋不老10-15份、通经草15-20份、香附6-9份、黄花稔8-12份、天葵草13-18份。
3.如权利要求2所述的药物组合物,其特征在于由以下重量份配比的药用原料制成:熟地黄12份、隔山消15份、千针万线草24份、玫瑰花10份、老鸦花藤15份、淫羊藿8份、蛋不老12份、通经草18份、香附8份、黄花稔11份、天葵草16份。
4.如权利要求1-3任一所述的药物组合物,其特征在于药物组合物可制成任何可药用的剂型。
5.如权利要求4所述的药物组合物,其特征在于所述药物组合物优选制成为口服剂型,如:软胶囊剂、胶囊剂、片剂、口服液、颗粒剂、丸剂、散剂、丹剂、膏剂。
6.如权利要求5所述的药物组合物,其特征在于所述口服剂型优选为片剂、胶囊剂或颗粒剂。
7.如权利要求6所述的药物组合物,其特征在于所述口服剂型优选为胶囊剂。
8.如权利要求1-3任一所述的药物组合物,其特征在于制备方法包括以下步骤:
按处方取熟地黄、隔山消、千针万线草、玫瑰花、老鸦花藤、淫羊藿、蛋不老、通经草、香附、黄花稔、天葵草,加4~7倍药材总重量的水提取2-3次,每次1~2小时,合并提取液,过滤,减压浓缩至相对密度为1.05-1.10(60℃测得),加乙醇使含醇量达45-50%(体积比),搅拌,静置过夜,过滤,滤液减压浓缩回收乙醇,浓缩成稠膏,该稠膏单独和/或与药物可接受的载体混合为活性成分,依照制剂学常规技术制成。
9.权利要求1-3任一所述的药物组合物在制备治疗多囊卵巢综合征合并乳腺增生的药物中的用途。
10.权利要求1-3任一所述的药物组合物在制备治疗乳腺增生的药物中的用途。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610094506.2A CN105456620A (zh) | 2016-02-22 | 2016-02-22 | 一种用于治疗多囊卵巢综合征合并乳腺增生的药物组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610094506.2A CN105456620A (zh) | 2016-02-22 | 2016-02-22 | 一种用于治疗多囊卵巢综合征合并乳腺增生的药物组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105456620A true CN105456620A (zh) | 2016-04-06 |
Family
ID=55595077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610094506.2A Pending CN105456620A (zh) | 2016-02-22 | 2016-02-22 | 一种用于治疗多囊卵巢综合征合并乳腺增生的药物组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105456620A (zh) |
-
2016
- 2016-02-22 CN CN201610094506.2A patent/CN105456620A/zh active Pending
Non-Patent Citations (1)
| Title |
|---|
| 石显方等: "石景亮教授治疗多囊卵巢综合征的经验", 《浙江中医杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102362950A (zh) | 一种治疗白癜风的中药 | |
| CN102836409B (zh) | 用于治疗产后恶露不绝的中药及制备方法 | |
| CN105412787A (zh) | 治疗产后月经不调的药物 | |
| CN104524071A (zh) | 一种治疗原发性肾病的药物组合物及其用途 | |
| CN103977362A (zh) | 治疗乳腺增生及早期乳腺癌的中药组方 | |
| CN105213807A (zh) | 用于治疗阴虚火旺型复发性口腔溃疡的药物 | |
| CN105944020B (zh) | 一种治疗卵巢功能下降的中药 | |
| CN103191399A (zh) | 用于治疗支气管哮喘急性发作期的中药组合物 | |
| CN102579895B (zh) | 一种治疗银屑病的中药组合物 | |
| CN105770691A (zh) | 一种用于治疗宫颈癌的药物制剂及其用途 | |
| CN105497262A (zh) | 一种治疗肝肾阴虚型多囊卵巢综合征的药物组合物 | |
| CN105833209B (zh) | 一种治疗子宫内膜异位症的中药组合物 | |
| CN105456620A (zh) | 一种用于治疗多囊卵巢综合征合并乳腺增生的药物组合物 | |
| CN116889614B (zh) | 一种治疗男性不育的中药组合物及其应用 | |
| CN102552824B (zh) | 用于治疗银屑病的中成药 | |
| CN105395768A (zh) | 一种治疗气血两虚型月经量少的药物组合物 | |
| CN105597020A (zh) | 一种治疗多囊卵巢综合征合并乳腺增生的药物组合物 | |
| CN105535199A (zh) | 一种治疗多囊卵巢综合征合并乳腺增生的药物制剂 | |
| CN105535466A (zh) | 一种治疗青春期多囊卵巢综合征的药物组合物 | |
| CN105833013A (zh) | 一种治疗甲状腺癌术后复发甲状腺结节的药物组合物 | |
| CN105521370A (zh) | 一种用于治疗结肠癌的药物制剂及其用途 | |
| CN105288372A (zh) | 一种治疗原发性痛经伴痤疮的药物制剂 | |
| CN102228561B (zh) | 一种治疗蛇皮癣的中成药 | |
| CN105497400A (zh) | 一种治疗肾虚痰湿型月经过少的药物组合物 | |
| CN101028428A (zh) | 一种治疗卵巢囊肿的中药制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160406 |
|
| RJ01 | Rejection of invention patent application after publication |